WXXWY Wuxi Biologics Unsp/Adrs

WuXi Biologics (Cayman) Inc., an investment holding company, operates as an open-access technology platform company that provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the People's Republic of China and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology; international sales contracting services; testing and development of testing technologies; provision of biologics clinical and manufacturing services provision of sales and marketing services in the United States; production and sales of medicals; vaccine CDMO and related business; and material supplier activities. In addition, it provides clinical and commercial manufacturing, assay, formulation and process development, process validation, lot release testing, stability studies, drug product formulation, fill and finish, and regulatory support services for recombinant protein, monoclonal antibodies, and antibody drug conjugates. The company serves pharmaceutical and biotechnology companies. It has strategic partnerships with Amicus Therapeutics; ABL Bio; NBE-Therapeutics; I-Mab Biopharma; NovoCodex Biopharmaceuticals Co., Ltd.; Almirall; Antengene Corporation; and Arcus Biosciences, Inc. The company was founded in 2014 and is headquartered in Wuxi, China. WuXi Biologics (Cayman) Inc. is a subsidiary of WuXi Biologics Holdings Limited. This is an ADR of a company whose stock trades outside of the U.S. as the symbol HK:2269.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$26.30    Pink
As of 11/26/2021     OTCMarkets


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Large cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  China
Country of incorporation:  Cayman Islands
IPO date:  11/30/2018
Outstanding shares:  2,121,398,077
Average volume:  156,002
Market cap:   $56,450,402,829
Current dividend yield:  0.00%
CUSIP:    
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.65
PS ratio:   58.32
Return on equity:   0.12%
Net income %:   8.26%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy